Loading…

Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence

Objectives. To study the diagnostic performance of the ImmunoCyt test in patients in follow-up for superficial urothelial cell carcinoma (UCC) of the bladder. Methods. Voided urine samples were collected from all included patients. Samples were processed with the ImmunoCyt test. The ImmunoCyt slides...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) N.J.), 2001-09, Vol.58 (3), p.367-371
Main Authors: Vriesema, J.L.J, Atsma, F, Kiemeney, L.A.L.M, Peelen, W.P, Witjes, J.A, Schalken, J.A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c391t-67c92cfcc47d2d27ed5329dd199525467ae23ef0fccb0b9a61250ed7e18946683
cites cdi_FETCH-LOGICAL-c391t-67c92cfcc47d2d27ed5329dd199525467ae23ef0fccb0b9a61250ed7e18946683
container_end_page 371
container_issue 3
container_start_page 367
container_title Urology (Ridgewood, N.J.)
container_volume 58
creator Vriesema, J.L.J
Atsma, F
Kiemeney, L.A.L.M
Peelen, W.P
Witjes, J.A
Schalken, J.A
description Objectives. To study the diagnostic performance of the ImmunoCyt test in patients in follow-up for superficial urothelial cell carcinoma (UCC) of the bladder. Methods. Voided urine samples were collected from all included patients. Samples were processed with the ImmunoCyt test. The ImmunoCyt slides were scored under a fluorescence microscope by 3 observers. The ImmunoCyt test was considered positive if one or more observers scored the test positive. Urethrocystoscopy (and additional histologic examination in the case of suspicious cystoscopic findings) was used as the reference standard. To investigate the validity of ImmunoCyt, sensitivity, specificity, positive predictive value, negative predictive value, area under the receiver operating characteristic curve, and diagnostic odds ratios were determined. To investigate the reproducibility of ImmunoCyt, kappa values (measure of agreement) were computed. The observers’ findings were analyzed in pairs. Results. One hundred four patients in follow-up after primary superficial UCC of the bladder were included. Samples of 18 patients had to be excluded because of low cellularity (ie, insufficient assessable urothelial cells). Tumor recurrence was found in 22 of the remaining 86 patients (17 pTa, 3 pT1, 1 carcinoma in situ, 1 pT2 or higher). The test had a sensitivity of 50%, specificity of 73%, positive predictive value of 39%, and negative predictive value of 81%. The diagnostic odds ratio was 2.8 (95% confidence interval 1.0 to 7.5). The area under the curve for the different observers varied between 0.54 and 0.60. The kappa values were low (0.05 to 0.45), representing high interobserver variability. Conclusions. The promising results from other studies could not be confirmed in this specific group of patients in follow-up for superficial UCC of the bladder. The validity of ImmunoCyt was insufficient to justify the omission of cystoscopy in patients in follow-up for superficial UCC.
doi_str_mv 10.1016/S0090-4295(01)01217-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71153812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090429501012171</els_id><sourcerecordid>71153812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-67c92cfcc47d2d27ed5329dd199525467ae23ef0fccb0b9a61250ed7e18946683</originalsourceid><addsrcrecordid>eNqFkEtv1DAQgC0EotvCTwD5AiqHwIyT2PGpQuXRSpV6KBw4Wd7xBIySzWInSPvv8XZX9NjLzBy-eX1CvEJ4j4D6wx2AhapRtj0HfAeo0FT4RKywVaay1rZPxeo_ciJOc_4NAFpr81ycILaNbTq1Ej8-Rf9zM-U5kuS-j-RpJ6dezr9YXo_jsploN8uZcwmTDDwzzTIvW06FjX6Q68GHwEmS31BJiWlJiUv9Qjzr_ZD55TGfie9fPn-7vKpubr9eX368qai2OFfakFXUEzUmqKAMh7ZWNgQsL6i20cazqrmHQqxhbb1G1QIHw9jZRuuuPhNvD3O3afqzlEPdGDPxMPgNT0t2pjxbd6gK2B5ASlPOiXu3TXH0aecQ3N6pu3fq9sIcoLt36rD0vT4uWNYjh4euo8QCvDkCPpMf-lRUxPzANdAZ0FC4iwPHRcffyMllintVIRZtswtTfOSUf88Rk6Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71153812</pqid></control><display><type>article</type><title>Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence</title><source>Elsevier</source><creator>Vriesema, J.L.J ; Atsma, F ; Kiemeney, L.A.L.M ; Peelen, W.P ; Witjes, J.A ; Schalken, J.A</creator><creatorcontrib>Vriesema, J.L.J ; Atsma, F ; Kiemeney, L.A.L.M ; Peelen, W.P ; Witjes, J.A ; Schalken, J.A</creatorcontrib><description>Objectives. To study the diagnostic performance of the ImmunoCyt test in patients in follow-up for superficial urothelial cell carcinoma (UCC) of the bladder. Methods. Voided urine samples were collected from all included patients. Samples were processed with the ImmunoCyt test. The ImmunoCyt slides were scored under a fluorescence microscope by 3 observers. The ImmunoCyt test was considered positive if one or more observers scored the test positive. Urethrocystoscopy (and additional histologic examination in the case of suspicious cystoscopic findings) was used as the reference standard. To investigate the validity of ImmunoCyt, sensitivity, specificity, positive predictive value, negative predictive value, area under the receiver operating characteristic curve, and diagnostic odds ratios were determined. To investigate the reproducibility of ImmunoCyt, kappa values (measure of agreement) were computed. The observers’ findings were analyzed in pairs. Results. One hundred four patients in follow-up after primary superficial UCC of the bladder were included. Samples of 18 patients had to be excluded because of low cellularity (ie, insufficient assessable urothelial cells). Tumor recurrence was found in 22 of the remaining 86 patients (17 pTa, 3 pT1, 1 carcinoma in situ, 1 pT2 or higher). The test had a sensitivity of 50%, specificity of 73%, positive predictive value of 39%, and negative predictive value of 81%. The diagnostic odds ratio was 2.8 (95% confidence interval 1.0 to 7.5). The area under the curve for the different observers varied between 0.54 and 0.60. The kappa values were low (0.05 to 0.45), representing high interobserver variability. Conclusions. The promising results from other studies could not be confirmed in this specific group of patients in follow-up for superficial UCC of the bladder. The validity of ImmunoCyt was insufficient to justify the omission of cystoscopy in patients in follow-up for superficial UCC.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/S0090-4295(01)01217-1</identifier><identifier>PMID: 11549482</identifier><identifier>CODEN: URGYAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Biomarkers, Tumor ; Carcinoma, Transitional Cell - diagnosis ; Carcinoma, Transitional Cell - urine ; Confidence Intervals ; Cystoscopy ; Female ; Fluorescent Antibody Technique - methods ; Follow-Up Studies ; Humans ; Immunohistochemistry - methods ; Immunohistochemistry - statistics &amp; numerical data ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Odds Ratio ; Predictive Value of Tests ; Reproducibility of Results ; ROC Curve ; Sensitivity and Specificity ; Tumors of the urinary system ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - surgery ; Urinary Bladder Neoplasms - urine ; Urinary tract. Prostate gland ; Urine - cytology</subject><ispartof>Urology (Ridgewood, N.J.), 2001-09, Vol.58 (3), p.367-371</ispartof><rights>2001 Elsevier Science Inc.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-67c92cfcc47d2d27ed5329dd199525467ae23ef0fccb0b9a61250ed7e18946683</citedby><cites>FETCH-LOGICAL-c391t-67c92cfcc47d2d27ed5329dd199525467ae23ef0fccb0b9a61250ed7e18946683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14087060$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11549482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vriesema, J.L.J</creatorcontrib><creatorcontrib>Atsma, F</creatorcontrib><creatorcontrib>Kiemeney, L.A.L.M</creatorcontrib><creatorcontrib>Peelen, W.P</creatorcontrib><creatorcontrib>Witjes, J.A</creatorcontrib><creatorcontrib>Schalken, J.A</creatorcontrib><title>Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>Objectives. To study the diagnostic performance of the ImmunoCyt test in patients in follow-up for superficial urothelial cell carcinoma (UCC) of the bladder. Methods. Voided urine samples were collected from all included patients. Samples were processed with the ImmunoCyt test. The ImmunoCyt slides were scored under a fluorescence microscope by 3 observers. The ImmunoCyt test was considered positive if one or more observers scored the test positive. Urethrocystoscopy (and additional histologic examination in the case of suspicious cystoscopic findings) was used as the reference standard. To investigate the validity of ImmunoCyt, sensitivity, specificity, positive predictive value, negative predictive value, area under the receiver operating characteristic curve, and diagnostic odds ratios were determined. To investigate the reproducibility of ImmunoCyt, kappa values (measure of agreement) were computed. The observers’ findings were analyzed in pairs. Results. One hundred four patients in follow-up after primary superficial UCC of the bladder were included. Samples of 18 patients had to be excluded because of low cellularity (ie, insufficient assessable urothelial cells). Tumor recurrence was found in 22 of the remaining 86 patients (17 pTa, 3 pT1, 1 carcinoma in situ, 1 pT2 or higher). The test had a sensitivity of 50%, specificity of 73%, positive predictive value of 39%, and negative predictive value of 81%. The diagnostic odds ratio was 2.8 (95% confidence interval 1.0 to 7.5). The area under the curve for the different observers varied between 0.54 and 0.60. The kappa values were low (0.05 to 0.45), representing high interobserver variability. Conclusions. The promising results from other studies could not be confirmed in this specific group of patients in follow-up for superficial UCC of the bladder. The validity of ImmunoCyt was insufficient to justify the omission of cystoscopy in patients in follow-up for superficial UCC.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor</subject><subject>Carcinoma, Transitional Cell - diagnosis</subject><subject>Carcinoma, Transitional Cell - urine</subject><subject>Confidence Intervals</subject><subject>Cystoscopy</subject><subject>Female</subject><subject>Fluorescent Antibody Technique - methods</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Immunohistochemistry - statistics &amp; numerical data</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Odds Ratio</subject><subject>Predictive Value of Tests</subject><subject>Reproducibility of Results</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - surgery</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>Urinary tract. Prostate gland</subject><subject>Urine - cytology</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqFkEtv1DAQgC0EotvCTwD5AiqHwIyT2PGpQuXRSpV6KBw4Wd7xBIySzWInSPvv8XZX9NjLzBy-eX1CvEJ4j4D6wx2AhapRtj0HfAeo0FT4RKywVaay1rZPxeo_ciJOc_4NAFpr81ycILaNbTq1Ej8-Rf9zM-U5kuS-j-RpJ6dezr9YXo_jsploN8uZcwmTDDwzzTIvW06FjX6Q68GHwEmS31BJiWlJiUv9Qjzr_ZD55TGfie9fPn-7vKpubr9eX368qai2OFfakFXUEzUmqKAMh7ZWNgQsL6i20cazqrmHQqxhbb1G1QIHw9jZRuuuPhNvD3O3afqzlEPdGDPxMPgNT0t2pjxbd6gK2B5ASlPOiXu3TXH0aecQ3N6pu3fq9sIcoLt36rD0vT4uWNYjh4euo8QCvDkCPpMf-lRUxPzANdAZ0FC4iwPHRcffyMllintVIRZtswtTfOSUf88Rk6Y</recordid><startdate>20010901</startdate><enddate>20010901</enddate><creator>Vriesema, J.L.J</creator><creator>Atsma, F</creator><creator>Kiemeney, L.A.L.M</creator><creator>Peelen, W.P</creator><creator>Witjes, J.A</creator><creator>Schalken, J.A</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010901</creationdate><title>Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence</title><author>Vriesema, J.L.J ; Atsma, F ; Kiemeney, L.A.L.M ; Peelen, W.P ; Witjes, J.A ; Schalken, J.A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-67c92cfcc47d2d27ed5329dd199525467ae23ef0fccb0b9a61250ed7e18946683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor</topic><topic>Carcinoma, Transitional Cell - diagnosis</topic><topic>Carcinoma, Transitional Cell - urine</topic><topic>Confidence Intervals</topic><topic>Cystoscopy</topic><topic>Female</topic><topic>Fluorescent Antibody Technique - methods</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Immunohistochemistry - statistics &amp; numerical data</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Odds Ratio</topic><topic>Predictive Value of Tests</topic><topic>Reproducibility of Results</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - surgery</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>Urinary tract. Prostate gland</topic><topic>Urine - cytology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vriesema, J.L.J</creatorcontrib><creatorcontrib>Atsma, F</creatorcontrib><creatorcontrib>Kiemeney, L.A.L.M</creatorcontrib><creatorcontrib>Peelen, W.P</creatorcontrib><creatorcontrib>Witjes, J.A</creatorcontrib><creatorcontrib>Schalken, J.A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vriesema, J.L.J</au><au>Atsma, F</au><au>Kiemeney, L.A.L.M</au><au>Peelen, W.P</au><au>Witjes, J.A</au><au>Schalken, J.A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>2001-09-01</date><risdate>2001</risdate><volume>58</volume><issue>3</issue><spage>367</spage><epage>371</epage><pages>367-371</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><coden>URGYAZ</coden><abstract>Objectives. To study the diagnostic performance of the ImmunoCyt test in patients in follow-up for superficial urothelial cell carcinoma (UCC) of the bladder. Methods. Voided urine samples were collected from all included patients. Samples were processed with the ImmunoCyt test. The ImmunoCyt slides were scored under a fluorescence microscope by 3 observers. The ImmunoCyt test was considered positive if one or more observers scored the test positive. Urethrocystoscopy (and additional histologic examination in the case of suspicious cystoscopic findings) was used as the reference standard. To investigate the validity of ImmunoCyt, sensitivity, specificity, positive predictive value, negative predictive value, area under the receiver operating characteristic curve, and diagnostic odds ratios were determined. To investigate the reproducibility of ImmunoCyt, kappa values (measure of agreement) were computed. The observers’ findings were analyzed in pairs. Results. One hundred four patients in follow-up after primary superficial UCC of the bladder were included. Samples of 18 patients had to be excluded because of low cellularity (ie, insufficient assessable urothelial cells). Tumor recurrence was found in 22 of the remaining 86 patients (17 pTa, 3 pT1, 1 carcinoma in situ, 1 pT2 or higher). The test had a sensitivity of 50%, specificity of 73%, positive predictive value of 39%, and negative predictive value of 81%. The diagnostic odds ratio was 2.8 (95% confidence interval 1.0 to 7.5). The area under the curve for the different observers varied between 0.54 and 0.60. The kappa values were low (0.05 to 0.45), representing high interobserver variability. Conclusions. The promising results from other studies could not be confirmed in this specific group of patients in follow-up for superficial UCC of the bladder. The validity of ImmunoCyt was insufficient to justify the omission of cystoscopy in patients in follow-up for superficial UCC.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11549482</pmid><doi>10.1016/S0090-4295(01)01217-1</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-4295
ispartof Urology (Ridgewood, N.J.), 2001-09, Vol.58 (3), p.367-371
issn 0090-4295
1527-9995
language eng
recordid cdi_proquest_miscellaneous_71153812
source Elsevier
subjects Adult
Aged
Biological and medical sciences
Biomarkers, Tumor
Carcinoma, Transitional Cell - diagnosis
Carcinoma, Transitional Cell - urine
Confidence Intervals
Cystoscopy
Female
Fluorescent Antibody Technique - methods
Follow-Up Studies
Humans
Immunohistochemistry - methods
Immunohistochemistry - statistics & numerical data
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Odds Ratio
Predictive Value of Tests
Reproducibility of Results
ROC Curve
Sensitivity and Specificity
Tumors of the urinary system
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - surgery
Urinary Bladder Neoplasms - urine
Urinary tract. Prostate gland
Urine - cytology
title Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A02%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20efficacy%20of%20the%20Immunocyt%20test%20to%20detect%20superficial%20bladder%20cancer%20recurrence&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Vriesema,%20J.L.J&rft.date=2001-09-01&rft.volume=58&rft.issue=3&rft.spage=367&rft.epage=371&rft.pages=367-371&rft.issn=0090-4295&rft.eissn=1527-9995&rft.coden=URGYAZ&rft_id=info:doi/10.1016/S0090-4295(01)01217-1&rft_dat=%3Cproquest_cross%3E71153812%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c391t-67c92cfcc47d2d27ed5329dd199525467ae23ef0fccb0b9a61250ed7e18946683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71153812&rft_id=info:pmid/11549482&rfr_iscdi=true